PEAK6 Investments’s United Therapeutics UTHR Stock Holding History

PEAK6 Investments’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,200	Closed	-$2.51M	–	4747
2023 Q1	$2.51M	Buy	11,200 +9,900	+762%	+$2.44M	0.01%	1115
2022 Q4	$362K	Sell	1,300 -1,000	-43%	-$252K	﹤0.01%	2791
2022 Q3	$482K	Sell	2,300 -15,300	-87%	-$3.42M	﹤0.01%	2909
2022 Q2	$4.15M	Buy	17,600 +16,100	+1,073%	+$3.27M	0.01%	1548
2022 Q1	$269K	Buy	+1,500	New	+$286K	﹤0.01%	3655
2021 Q3	–	Sell	-5,000	Closed	-$897K	–	5842
2021 Q2	$897K	Buy	+5,000	New	+$952K	﹤0.01%	2680
2021 Q1	–	Sell	-15,000	Closed	-$2.28M	–	5570
2020 Q4	$2.28M	Buy	15,000 +2,400	+19%	+$315K	﹤0.01%	1747
2020 Q3	$1.27M	Sell	12,600 -1,200	-9%	-$132K	﹤0.01%	2062
2020 Q2	$1.67M	Buy	13,800 +10,700	+345%	+$1.2M	0.01%	1640
2020 Q1	$294K	Buy	+3,100	New	+$295K	﹤0.01%	2506

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PEAK6 Investments's UTHR Position: Q3 2023 in Review

PEAK6 Investments sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 3 shares — an estimated $651 sold.

PEAK6 Investments first reported a position in UTHR in Q1 2019 and held it in 11 quarters. The position peaked at $11.2M in Q2 2019. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

PEAK6 Investments reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
PEAK6 Investments sold 3 United Therapeutics shares in Q3 2023, an estimated $651.
PEAK6 Investments first reported a position in United Therapeutics in Q1 2019 and held it in 11 quarters.
PEAK6 Investments's United Therapeutics position peaked at $11.2M in Q2 2019.
508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.